Oral IL-23 Inhibitor Shows Long-Term Safety, Efficacy in UC
Medscape reports long-term extension results from the phase 2b ANTHEM-UC trial, presented at ACG 2026, of once-daily oral icotrokinra, an IL-23 inhibitor, in moderate-to-severe ulcerative colitis. Of 136 patients who had responded by week 28 and entered the extension, 85% stayed on treatment through week 76. Clinical remission ranged from 56.3% to 59.1% across doses. No new safety signals were reported. Johnson & Johnson funded the study.
Why it matters: Relevant to Maryland adults living with moderate-to-severe ulcerative colitis and to the gastroenterologists and other clinicians who refer them for advanced therapy.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medscape.com. October 14, 2026.
